Conclusions
death
The COMET-ICE trial was designed to test pandemic-relevant serious clinical outcomes (hospitalization or death) and demonstrated a clinical benefit of sotrovimab treatment. The current study adds to these findings by demonstrating significant and rapid improvements in patient-reported COVID-19 symptoms, as measured by the FLU-PRO Plus questionnaire in both total and individual domain scores, with patients noticing a benefit within a week of treatment administration.